Novo Nordisk A/S (NVO) - 40.37% Below 52-Week High: Buy or Wait?

Stock Details

Novo Nordisk A/S (NVO), a prominent company in the healthcare sector within the drug manufacturers - general industry, is based in Denmark and primarily trades on the NYQ.Currently, the stock is trading at $38.26. Over the past 52 weeks, it has ranged between $35.12 and $64.16. This places the current price at 59.6% of its 52-week high and 8.9% above its 52-week low. Recent trading volume was recorded at 13,648,649. The 14-day Relative Strength Index (RSI) stands at 28.77, suggesting oversold conditions. The stock is currently trading below its 50-day moving average of $44.46 by 13.95%. Similarly, it is below its 200-day moving average of $45.54 by 15.99%. The MACD histogram is -0.12, indicating bearish momentum (MACD Line: -2.09, Signal Line: -1.96). The International Securities Identification Number (ISIN) for this stock is US6701002056.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

9.18

Below market average

Forward P/E

11.29

Earnings expected to decline

PEG Ratio

4.33

Potentially overvalued

Price to Book

4.99

EV/EBITDA

1.50

EPS (TTM)

$4.09

Price to Sales

0.50

Beta

0.38

Less volatile than market

Q:How is NVO valued relative to its earnings and growth?

Novo Nordisk A/S trades at a P/E ratio of 9.18, which is below the market average of approximately 20. This lower valuation could indicate the market has modest growth expectations, or it might represent an undervalued opportunity if the fundamentals are strong. Looking ahead, the forward P/E of 11.29 is higher than the current P/E, indicating analysts expect earnings to decline over the next year. The PEG ratio of 4.33 indicates a premium valuation even accounting for growth.

Q:What is NVO's risk profile compared to the market?

With a beta of 0.38, Novo Nordisk A/S is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 4.99 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

35.35%

Operating Margin

42.54%

EBITDA

$173.68B

Return on Equity

59.81%

Return on Assets

18.73%

Revenue Growth (YoY)

2.10%

Earnings Growth (YoY)

-20.60%

Q:How profitable and efficient is NVO's business model?

Novo Nordisk A/S achieves a profit margin of 35.35%, meaning it retains $35.35 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 42.54% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 59.81% and ROA at 18.73%, the company generates strong returns on invested capital.

Q:What are NVO's recent growth trends?

Novo Nordisk A/S's revenue grew by 2.10% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings decreased by 20.60% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against Drug Manufacturers - General industry averages for proper context.

Dividend Information

Dividend Per Share

$1.80

Dividend Yield

4.79%

Ex-Dividend Date

Aug 17, 2026

Dividend Date

Aug 25, 2026

Q:What dividend income can investors expect from NVO?

Novo Nordisk A/S offers a dividend yield of 4.79%, paying $1.80 per share annually. This high yield exceeds 4%, significantly outperforming the S&P 500 average of 1.5-2% and most investment-grade bonds. For income-focused investors, this represents an attractive cash flow opportunity, though high yields sometimes signal market concerns about sustainability. To receive the next dividend, shares must be purchased before the ex-dividend date of Aug 17, 2026.

Q:How reliable is NVO's dividend for long-term investors?

The dividend sustainability can be assessed through the payout ratio - Novo Nordisk A/S pays $1.80 per share in dividends against earnings of $4.09 per share, resulting in a payout ratio of 44.01%. This balanced payout between 30-60% suggests a sustainable dividend policy that allows both shareholder returns and business reinvestment. The dividend appears well-covered by earnings. The next dividend payment is scheduled for Aug 25, 2026.

Company Size & Market

Market Cap

$165.7B

Revenue (TTM)

$329.43B

Revenue/Share (TTM)

$74.19

Shares Outstanding

3.34B

Book Value/Share

$7.52

Asset Type

EQUITY

Q:What is NVO's market capitalization and position?

Novo Nordisk A/S has a market capitalization of $165.7B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 3.34B shares outstanding, the company's ownership is widely distributed. As a major player in the Drug Manufacturers - General industry, it competes with other firms in this sector.

Q:How does NVO's price compare to its book value?

Novo Nordisk A/S's book value per share is $7.52, while the current stock price is $38.26, resulting in a price-to-book (P/B) ratio of 5.09. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$46.14

20.60% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for NVO?

13 analysts cover NVO with 54% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $46.14 implies 20.6% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on NVO?

Current analyst recommendations:1 Strong Buy, 6 Buy, 5 Hold, 1 Sell, 0The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Oct 7, 2026, 02:05 AM

Technical Indicators

RSI (14-day)

28.77

Oversold

50-Day Moving Average

$44.46

-13.95% below MA-50

200-Day Moving Average

$45.54

-15.99% below MA-200

MACD Line

-2.09

MACD Signal

-1.96

MACD Histogram

-0.12

Bearish

Q:What does NVO's RSI value tell investors?

The RSI (Relative Strength Index) for NVO is currently 28.77, indicating the stock is in oversold territory (below 30). This indicates heavy selling pressure that may have pushed the price too low too fast. Oversold readings can present buying opportunities, but stocks can remain oversold in strong downtrends. Look for RSI to rise above 30 as a potential recovery signal. Combined with the price being below the 50-day moving average, this confirms bearish conditions.

Q:How should traders interpret NVO's MACD and moving average crossovers?

MACD analysis shows the MACD line at -2.09 below the signal line at -1.96, with histogram at -0.12. This bearish crossover indicates downward pressure. The 50-day MA ($44.46) is below the 200-day MA ($45.54), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Oct 7, 2026, 01:23 AM

Novo Nordisk A/S (NVO) Stock